Shared decision-making for supporting women's decisions about breast cancer screening.

Paula Riganti, M Victoria Ruiz Yanzi, Camila Micaela Escobar Liquitay, Nadia J Sgarbossa, Christoper A Alarcon-Ruiz, Karin S Kopitowski, Juan Va Franco
Author Information
  1. Paula Riganti: Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  2. M Victoria Ruiz Yanzi: Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  3. Camila Micaela Escobar Liquitay: Associate Cochrane Centre, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  4. Nadia J Sgarbossa: Health Department, Universidad Nacional de La Matanza, Buenos Aires, Argentina.
  5. Christoper A Alarcon-Ruiz: Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru.
  6. Karin S Kopitowski: Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  7. Juan Va Franco: Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

Abstract

BACKGROUND: In breast cancer screening programmes, women may have discussions with a healthcare provider to help them decide whether or not they wish to join the breast cancer screening programme. This process is called shared decision-making (SDM) and involves discussions and decisions based on the evidence and the person's values and preferences. SDM is becoming a recommended approach in clinical guidelines, extending beyond decision aids. However, the overall effect of SDM in women deciding to participate in breast cancer screening remains uncertain.
OBJECTIVES: To assess the effect of SDM on women's satisfaction, confidence, and knowledge when deciding whether to participate in breast cancer screening.
SEARCH METHODS: We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform on 8 August 2023. We also screened abstracts from two relevant conferences from 2020 to 2023.
SELECTION CRITERIA: We included parallel randomised controlled trials (RCTs) and cluster-RCTs assessing interventions targeting various components of SDM. The focus was on supporting women aged 40 to 75 at average or above-average risk of breast cancer in their decision to participate in breast cancer screening.
DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion and conducted data extraction, risk of bias assessment, and GRADE assessment of the certainty of the evidence. Review outcomes included satisfaction with the decision-making process, confidence in the decision made, knowledge of all options, adherence to the chosen option, women's involvement in SDM, woman-clinician communication, and mental health.
MAIN RESULTS: We identified 19 studies with 64,215 randomised women, mostly with an average to moderate risk of breast cancer. Two studies covered all aspects of SDM; six examined shortened forms of SDM involving communication on risks and personal values; and 11 focused on enhanced communication of risk without other SDM aspects. SDM involving all components compared to control The two eligible studies did not assess satisfaction with the SDM process or confidence in the decision. Based on a single study, SDM showed uncertain effects on participant knowledge regarding the age to start screening (risk ratio (RR) 1.18, 95% confidence interval (CI) 0.61 to 2.28; 133 women; very low certainty evidence) and frequency of testing (RR 0.84, 95% CI 0.68 to 1.04; 133 women; very low certainty evidence). Other review outcomes were not measured. Abbreviated forms of SDM with clarification of values and preferences compared to control Of the six included studies, none evaluated satisfaction with the SDM process. These interventions may reduce conflict in the decision made, based on two measures, Decisional Conflict Scale scores (mean difference (MD) -1.60, 95% CI -4.21 to 0.87; conflict scale from 0 to 100; 4 studies; 1714 women; very low certainty evidence) and the proportion of women with residual conflict compared to control at one to three months' follow-up (rate of women with a conflicted decision, RR 0.75, 95% CI 0.56 to 0.99; 1 study; 1001 women, very low certainty evidence). Knowledge of all options was assessed through knowledge scores and informed choice. The effect of SDM may enhance knowledge (MDs ranged from 0.47 to 1.44 higher scores on a scale from 0 to 10; 5 studies; 2114 women; low certainty evidence) and may lead to higher rates of informed choice (RR 1.24, 95% CI 0.95 to 1.63; 4 studies; 2449 women; low certainty evidence) compared to control at one to three months' follow-up. These interventions may result in little to no difference in anxiety (MD 0.54, 95% -0.96 to 2.14; scale from 20 to 80; 2 studies; 749 women; low certainty evidence) and the number of women with worries about cancer compared to control at four to six weeks' follow-up (RR 0.88, 95% CI 0.73 to 1.06; 1 study, 639 women; low certainty evidence). Other review outcomes were not measured. Enhanced communication about risks without other SDM aspects compared to control Of 11 studies, three did not report relevant outcomes for this review, and none assessed satisfaction with the SDM process. Confidence in the decision made was measured by decisional conflict and anticipated regret of participating in screening or not. These interventions, without addressing values and preferences, may result in lower confidence in the decision compared to regular communication strategies at two weeks' follow-up (MD 2.89, 95% CI -2.35 to 8.14; Decisional Conflict Scale from 0 to 100; 2 studies; 1191 women; low certainty evidence). They may result in higher anticipated regret if participating in screening (MD 0.28, 95% CI 0.15 to 0.41) and lower anticipated regret if not participating in screening (MD -0.28, 95% CI -0.42 to -0.14). These interventions increase knowledge (MD 1.14, 95% CI 0.61 to 1.62; scale from 0 to 10; 4 studies; 2510 women; high certainty evidence), while it is unclear if there is a higher rate of informed choice compared to regular communication strategies at two to four weeks' follow-up (RR 1.27, 95% CI 0.83 to 1.92; 2 studies; 1805 women; low certainty evidence). These interventions result in little to no difference in anxiety (MD 0.33, 95% CI -1.55 to 0.99; scale from 20 to 80) and depression (MD 0.02, 95% CI -0.41 to 0.45; scale from 0 to 21; 2 studies; 1193 women; high certainty evidence) and lower cancer worry compared to control (MD -0.17, 95% CI -0.26 to -0.08; scale from 1 to 4; 1 study; 838 women; high certainty evidence). Other review outcomes were not measured.
AUTHORS' CONCLUSIONS: Studies using abbreviated forms of SDM and other forms of enhanced communications indicated improvements in knowledge and reduced decisional conflict. However, uncertainty remains about the effect of SDM on supporting women's decisions. Most studies did not evaluate outcomes considered important for this review topic, and those that did measured different concepts. High-quality randomised trials are needed to evaluate SDM in diverse cultural settings with a focus on outcomes such as women's satisfaction with choices aligned to their values.

Associated Data

ClinicalTrials.gov | NCT00247442; NCT04741503; NCT01361035; NCT04948983

References

  1. J Health Commun. 2020 Sep 1;25(9):681-691 [PMID: 33111640]
  2. Patient Educ Couns. 2005 Jun;57(3):294-9 [PMID: 15893211]
  3. Patient Educ Couns. 2006 Mar;60(3):301-12 [PMID: 16051459]
  4. Contemp Clin Trials. 2018 Aug;71:1-8 [PMID: 29803815]
  5. Prev Med. 1995 Sep;24(5):477-84 [PMID: 8524722]
  6. AIMS Public Health. 2016 Nov 18;3(4):933-955 [PMID: 29546205]
  7. Patient Educ Couns. 2010 Jul;80(1):94-9 [PMID: 19879711]
  8. Front Public Health. 2019 Mar 12;7:46 [PMID: 30931291]
  9. J Clin Nurs. 2021 Nov 4;: [PMID: 34738288]
  10. Med Decis Making. 1996 Jan-Mar;16(1):58-64 [PMID: 8717600]
  11. Ann Fam Med. 2017 May;15(3):217-224 [PMID: 28483886]
  12. BMJ Evid Based Med. 2018 Aug;23(4):137-139 [PMID: 30002077]
  13. J Asthma. 2011 Dec;48(10):1022-31 [PMID: 22022958]
  14. BMJ Open. 2017 Oct 6;7(10):e016246 [PMID: 28988168]
  15. BMC Res Notes. 2018 May 21;11(1):332 [PMID: 29784009]
  16. Br J Cancer Suppl. 1996 Sep;29:S42-6 [PMID: 8782798]
  17. Health Care Women Int. 2006 Jan;27(1):59-74 [PMID: 16338740]
  18. Res Involv Engagem. 2021 Jul 22;7(1):52 [PMID: 34294148]
  19. Patient Educ Couns. 2015 Aug;98(8):961-9 [PMID: 25959986]
  20. Contemp Clin Trials. 2014 Jul;38(2):350-4 [PMID: 24952281]
  21. Am J Prev Med. 2020 Sep;59(3):343-354 [PMID: 32828322]
  22. Ann Fam Med. 2014 May-Jun;12(3):270-5 [PMID: 24821899]
  23. PLoS One. 2019 Mar 26;14(3):e0214057 [PMID: 30913217]
  24. Prev Med. 2001 Oct;33(4):325-32 [PMID: 11570837]
  25. Br J Gen Pract. 2016 Mar;66(644):116-7 [PMID: 26917633]
  26. Transl Behav Med. 2017 Jun;7(2):309-319 [PMID: 28097625]
  27. Qual Saf Health Care. 2003 Apr;12(2):93-9 [PMID: 12679504]
  28. Am J Prev Med. 2002 May;22(4):247-57 [PMID: 11988381]
  29. Med Decis Making. 2014 Jan;34(1):54-62 [PMID: 23776141]
  30. N Engl J Med. 2012 Nov 22;367(21):1998-2005 [PMID: 23171096]
  31. J Cancer Educ. 2015 Jun;30(2):244-52 [PMID: 25077769]
  32. Thorax. 2005 Mar;60(3):199-205 [PMID: 15741435]
  33. BMJ Open. 2014 May 15;4(5):e004990 [PMID: 24833692]
  34. BMJ. 2021 Mar 29;372:n71 [PMID: 33782057]
  35. Prev Med. 1993 May;22(3):350-60 [PMID: 8327418]
  36. Oncotarget. 2016 Mar 15;7(11):12885-92 [PMID: 26883201]
  37. J Cancer Educ. 2014 Mar;29(1):136-43 [PMID: 24132541]
  38. Med Decis Making. 1995 Jan-Mar;15(1):25-30 [PMID: 7898294]
  39. Soc Sci Med. 1997 Mar;44(5):681-92 [PMID: 9032835]
  40. J Community Genet. 2022 Feb;13(1):137-141 [PMID: 35060087]
  41. J Natl Med Assoc. 2011 Aug;103(8):762-8 [PMID: 22046855]
  42. J Gen Intern Med. 2003 Nov;18(11):875-83 [PMID: 14687272]
  43. BMC Womens Health. 2008 Oct 20;8:18 [PMID: 18937844]
  44. Breast J. 2017 Mar;23(2):210-214 [PMID: 28252231]
  45. Recent Results Cancer Res. 2018;210:207-221 [PMID: 28924688]
  46. J Natl Cancer Inst. 2021 Nov 2;113(11):1523-1530 [PMID: 33871631]
  47. Med Decis Making. 2015 Oct;35(7):847-58 [PMID: 26044208]
  48. Z Evid Fortbild Qual Gesundhwes. 2011;105(4):313-24 [PMID: 21620327]
  49. Med Decis Making. 2012 May-Jun;32(3):E22-33 [PMID: 22505617]
  50. BMJ Open. 2014 Sep 25;4(9):e006016 [PMID: 25256188]
  51. Ann Fam Med. 2017 Jan;15(1):48-55 [PMID: 28376460]
  52. Z Evid Fortbild Qual Gesundhwes. 2022 Jun;171:113-116 [PMID: 35610135]
  53. J Clin Epidemiol. 2016 Sep;77:15-23 [PMID: 27185074]
  54. Patient Educ Couns. 2016 Oct;99(10):1647-56 [PMID: 27178707]
  55. MDM Policy Pract. 2019 Jan 17;4(1):2381468318812889 [PMID: 30729166]
  56. Prev Med. 1998 Nov-Dec;27(6):862-70 [PMID: 9922069]
  57. Prev Med. 2000 Mar;30(3):200-8 [PMID: 10684743]
  58. PLoS One. 2017 Dec 13;12(12):e0189148 [PMID: 29236722]
  59. Med Decis Making. 2022 Aug;42(6):808-821 [PMID: 35209775]
  60. J Comp Eff Res. 2020 Oct;9(14):985-1002 [PMID: 33025800]
  61. Cochrane Database Syst Rev. 2020 Mar 25;3:CD013251 [PMID: 32212174]
  62. BMC Fam Pract. 2013 Aug 06;14:111 [PMID: 23915256]
  63. Recenti Prog Med. 2018 Feb;109(2):139-142 [PMID: 29493642]
  64. Breast Cancer Res. 2007;9(5):213 [PMID: 17888188]
  65. N Engl J Med. 2012 Mar 1;366(9):780-1 [PMID: 22375967]
  66. BMC Med Inform Decis Mak. 2017 Mar 21;17(1):29 [PMID: 28327125]
  67. Z Evid Fortbild Qual Gesundhwes. 2022 Jun;171:62-67 [PMID: 35606310]
  68. Prog Mol Biol Transl Sci. 2017;151:1-32 [PMID: 29096890]
  69. J Prev Health Promot. 2022 Aug;3(3):271-299 [PMID: 38566802]
  70. Prev Med. 2004 Sep;39(3):435-40 [PMID: 15313081]
  71. J Am Assoc Nurse Pract. 2020 Jan 16;33(4):324-330 [PMID: 31972786]
  72. J Womens Health (Larchmt). 2012 May;21(5):557-66 [PMID: 22416791]
  73. Br J Cancer. 2019 Aug;121(4):285-292 [PMID: 31285590]
  74. Z Evid Fortbild Qual Gesundhwes. 2022 Jun;171:6-10 [PMID: 35610132]
  75. N Engl J Med. 2011 Sep 15;365(11):1025-32 [PMID: 21916640]
  76. Lancet. 2015 Apr 25;385(9978):1642-52 [PMID: 25701273]
  77. Dtsch Arztebl Int. 2015 Jan 30;112(5):61-8 [PMID: 25686383]
  78. J Cancer Educ. 2005 Winter;20(4):247-50 [PMID: 16497138]
  79. BMJ Open. 2018 Dec 28;8(12):e023789 [PMID: 30593552]
  80. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [PMID: 17392385]
  81. PLoS One. 2022 Mar 16;17(3):e0265401 [PMID: 35294494]
  82. BMJ. 2017 Dec 5;359:j5224 [PMID: 29208760]
  83. PLoS One. 2020 Jan 10;15(1):e0226610 [PMID: 31923178]
  84. J Clin Epidemiol. 2022 Oct;150:216-224 [PMID: 35934265]
  85. Cochrane Database Syst Rev. 2020 Jan 25;1:CD013128 [PMID: 31981369]
  86. JAMA. 2018 May 1;319(17):1814-1815 [PMID: 29715344]
  87. J Clin Epidemiol. 2020 Mar;119:126-135 [PMID: 31711912]
  88. Patient Educ Couns. 2014 Sep;96(3):281-6 [PMID: 25034637]
  89. Patient Educ Couns. 2020 Jul 2;: [PMID: 32732022]
  90. BMJ. 2016 Oct 12;355:i4919 [PMID: 27733354]
  91. J Cancer Educ. 2018 Feb;33(1):67-73 [PMID: 27251634]
  92. Patient Educ Couns. 2010 Oct;81(1):63-72 [PMID: 20149953]
  93. Contemp Clin Trials. 2021 Mar;102:106271 [PMID: 33503497]
  94. Transl Behav Med. 2017 Sep;7(3):547-556 [PMID: 28452044]
  95. J Cancer Educ. 2022 Apr;37(2):338-342 [PMID: 32651766]
  96. Z Evid Fortbild Qual Gesundhwes. 2022 Jun;171:89-92 [PMID: 35610129]
  97. J Womens Health (Larchmt). 2015 Dec;24(12):1013-20 [PMID: 26360918]
  98. Trials. 2017 Sep 12;18(1):426 [PMID: 28899412]
  99. CMAJ. 2001 Aug 21;165(4):438-9 [PMID: 11531054]
  100. J Gen Intern Med. 1999 Feb;14(2):104-11 [PMID: 10051781]
  101. J Gen Intern Med. 2012 Oct;27(10):1361-7 [PMID: 22618581]
  102. J Cancer Educ. 2000 Spring;15(1):46-50 [PMID: 10730804]
  103. Eur J Public Health. 2021 Oct 11;31(4):873-883 [PMID: 34148093]
  104. BMJ. 2011 Jul 28;343:d4411 [PMID: 21798968]
  105. Psicothema. 2015;27(2):128-33 [PMID: 25927692]
  106. Curr Oncol. 2018 Jun;25(Suppl 1):S115-S124 [PMID: 29910654]
  107. Contemp Clin Trials. 2017 May;56:25-33 [PMID: 28257920]
  108. J Gen Intern Med. 2019 Apr;34(4):591-597 [PMID: 30091121]
  109. Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):271-6 [PMID: 8019378]
  110. Br J Cancer. 2016 Jan 19;114(2):171-6 [PMID: 26784123]
  111. BMC Med Inform Decis Mak. 2015 Nov 10;15:89 [PMID: 26554555]
  112. J Med Screen. 2009;16(2):81-4 [PMID: 19564520]
  113. J Rheumatol. 2019 Oct;46(10):1409-1414 [PMID: 30709963]
  114. Trials. 2013 Oct 01;14:319 [PMID: 24083811]
  115. Can Fam Physician. 2017 Sep;63(9):682-684 [PMID: 28904031]
  116. Patient Educ Couns. 2003 Jul;50(3):247-53 [PMID: 12900094]
  117. Am J Manag Care. 2003 Jan;9(1):33-44 [PMID: 12549813]
  118. J Gen Intern Med. 2020 Jun;35(6):1668-1677 [PMID: 32193817]
  119. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007297 [PMID: 20091628]
  120. Z Evid Fortbild Qual Gesundhwes. 2022 Jun;171:11-14 [PMID: 35610137]
  121. Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):584-92 [PMID: 27196092]
  122. BMJ. 2019 Aug 28;366:l4898 [PMID: 31462531]
  123. JAMA Intern Med. 2015 Sep;175(9):1483-9 [PMID: 26147578]
  124. Patient Educ Couns. 2002 Sep;48(1):87-91 [PMID: 12220754]
  125. BMC Health Serv Res. 2010 Sep 23;10:280 [PMID: 20863395]
  126. Eur J Public Health. 2012 Jun;22(3):413-8 [PMID: 21746751]
  127. Health Expect. 2019 Apr;22(2):193-200 [PMID: 30334315]
  128. BMJ Open. 2020 Jun 11;10(6):e034061 [PMID: 32532766]
  129. J Clin Epidemiol. 2016 Jun;74:119-23 [PMID: 26780258]
  130. Am J Health Promot. 2020 Jul;34(6):681-685 [PMID: 31986899]
  131. J Womens Health (Larchmt). 2018 Mar;27(3):317-323 [PMID: 28933653]
  132. Cancer. 2007 Jan 15;109(2 Suppl):386-95 [PMID: 17133417]
  133. J Womens Health (Larchmt). 2021 Nov;30(11):1529-1537 [PMID: 34582721]
  134. J Natl Cancer Inst. 2017 Jan 27;109(5): [PMID: 28130475]
  135. Aust N Z J Public Health. 2005 Feb;29(1):69-77 [PMID: 15782876]
  136. J Gen Intern Med. 2014 Aug;29(8):1113-21 [PMID: 24590734]
  137. Cochrane Database Syst Rev. 2017 Oct 03;10:CD012330 [PMID: 28972652]
  138. Health Expect. 2007 Dec;10(4):364-79 [PMID: 17986073]
  139. Patient Educ Couns. 2003 Jul;50(3):311-22 [PMID: 12900105]
  140. Ann Intern Med. 2016 Feb 16;164(4):279-96 [PMID: 26757170]
  141. Patient Educ Couns. 2012 Aug;88(2):284-90 [PMID: 22480628]
  142. J Health Econ. 2018 Mar;58:228-252 [PMID: 29571095]
  143. Gac Sanit. 2021 May-Jun;35(3):243-249 [PMID: 32173050]
  144. Fam Pract Manag. 2017 May/Jun;24(3):5-10 [PMID: 28671358]
  145. J Natl Cancer Inst. 2008 Mar 5;100(5):333-46 [PMID: 18314473]
  146. Health Expect. 2016 Oct;19(5):1160-8 [PMID: 26364752]
  147. BMJ Evid Based Med. 2023 Aug;28(4):260-266 [PMID: 36693715]
  148. J Fam Pract. 1990 May;30(5):542-7 [PMID: 2332744]
  149. Nurs Open. 2021 Sep;8(5):2091-2104 [PMID: 33377613]
  150. Cancer Control. 2005 Nov;12 Suppl 2:107-10 [PMID: 16327761]
  151. Women Health. 2013;53(6):552-71 [PMID: 23937729]
  152. Prev Med. 2002 Jul;35(1):87-96 [PMID: 12079445]
  153. J Cancer Educ. 2007 Spring;22(1):25-31 [PMID: 17570805]
  154. Health Care Women Int. 2007 Nov-Dec;28(10):872-87 [PMID: 17987458]
  155. BMJ. 2013 Jan 23;346:f158 [PMID: 23344309]
  156. Mayo Clin Proc. 2006 Jun;81(6):783-91 [PMID: 16770979]
  157. J Adv Nurs. 1993 Jul;18(7):1133-40 [PMID: 8370905]
  158. J Surg Oncol. 2012 Jan;105(1):48-54 [PMID: 21882193]
  159. CMAJ. 2018 Dec 10;190(49):E1441-E1451 [PMID: 30530611]
  160. CA Cancer J Clin. 2018 Nov;68(6):394-424 [PMID: 30207593]
  161. Arch Intern Med. 2007 Oct 22;167(19):2039-46 [PMID: 17954796]
  162. JAMA. 2015 Oct 20;314(15):1599-614 [PMID: 26501536]
  163. BMJ Open. 2017 Oct 06;7(10):e016894 [PMID: 28988175]
  164. Cochrane Database Syst Rev. 2017 Apr 12;4:CD001431 [PMID: 28402085]
  165. Transl Behav Med. 2019 Mar 1;9(2):328-335 [PMID: 29796649]
  166. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):201-10 [PMID: 20056639]
  167. Cancer Med. 2015 Dec;4(12):1923-32 [PMID: 26377150]
  168. Br J Cancer. 2020 Sep;123(5):714-721 [PMID: 32546834]
  169. J Cancer Educ. 1998 Fall;13(3):152-61 [PMID: 10898560]
  170. BMC Womens Health. 2015 Jul 22;15:53 [PMID: 26198675]
  171. BMC Cancer. 2017 Jun 19;17(1):429 [PMID: 28629329]
  172. Patient Educ Couns. 2012 Nov;89(2):353-9 [PMID: 22963769]
  173. JMIR Form Res. 2018 Nov 07;2(2):e24 [PMID: 30684421]
  174. Patient Educ Couns. 2011 Jul;84(1):128-31 [PMID: 20638219]
  175. Med Care. 2017 Oct;55(10):879-885 [PMID: 28857962]
  176. Rev Med Brux. 2018;39(4):410-415 [PMID: 30321008]
  177. Lancet. 2012 Nov 17;380(9855):1778-86 [PMID: 23117178]
  178. BMJ. 2003 Sep 6;327(7414):557-60 [PMID: 12958120]

MeSH Term

Adult
Aged
Female
Humans
Middle Aged
Breast Neoplasms
Decision Making, Shared
Early Detection of Cancer
Mammography
Patient Participation
Patient Satisfaction
Randomized Controlled Trials as Topic

Word Cloud

Created with Highcharts 10.0.00womenSDMevidencestudies95%certainty1CIcancerscreeninglowcomparedMDbreastdecision-0mayknowledgeoutcomescontrol2scalesatisfactioninterventionsreviewcommunicationRRprocessvalueswomen'sconfidencetworiskmeasuredconflictfollow-upeffectformsstudy4higherresult14decision-makingdecisionspreferencesparticipateincludedrandomisedsupportingassessedmadeaspectssixwithout28scoresdifferencethreeinformedchoiceweeks'anticipatedregretparticipatinglowerhighdiscussionswhetherbasedHoweverdecidingremainsuncertainassess82023relevanttrialscomponentsfocus75averageTwoassessmentoptionsinvolvingrisks11enhanced61133noneDecisionalConflictScale-121100onemonths'rate9910littleanxiety2080fourdecisionalregularstrategies41evaluateBACKGROUND:programmeshealthcareproviderhelpdecidewishjoinprogrammecalledsharedinvolvesperson'sbecomingrecommendedapproachclinicalguidelinesextendingbeyondaidsoverallOBJECTIVES:SEARCHMETHODS:searchedCochraneBreastCancerGroup'sSpecialisedRegisterCENTRALMEDLINEEmbaseCINAHLPsycINFOClinicalTrialsgovWorldHealthOrganizationInternationalClinicalTrialsRegistryPlatformAugustalsoscreenedabstractsconferences2020SELECTIONCRITERIA:parallelcontrolledRCTscluster-RCTsassessingtargetingvariousaged40above-averageDATACOLLECTIONANDANALYSIS:authorsindependentlyinclusionconducteddataextractionbiasGRADEReviewadherencechosenoptioninvolvementwoman-clinicianmentalhealthMAINRESULTS:identified1964215mostlymoderatecoveredexaminedshortenedpersonalfocusedeligibleBasedsingleshowedeffectsparticipantregardingagestartratio18intervalfrequencytesting846804Abbreviatedclarificationevaluatedreducemeasuresmean60-4871714proportionresidualconflicted561001KnowledgeenhanceMDsranged474452114leadrates24956324495496749numberworries887306639EnhancedreportConfidenceaddressing89-23511911542increase622510unclear27839218053355depression02451193worry172608838AUTHORS'CONCLUSIONS:StudiesusingabbreviatedcommunicationsindicatedimprovementsreduceduncertaintyconsideredimportanttopicdifferentconceptsHigh-qualityneededdiverseculturalsettingschoicesalignedShared

Similar Articles

Cited By